Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:17:22.880Z.
Calculation as of: 2026-10-06T19:17:22.880Z.
Quote observation: 2026-10-06T19:15:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
LB Pharmaceuticals Inc Common Stock
Market Cap
$984.47M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$986.75M
EV/Sales Ratio
2.40x
TTM Avg
16.24x
3Y Avg
25.95x
5Y Avg
23.23x
Market Cap
$971.96M
EV/Sales Ratio
1.58x
TTM Avg
1.77x
3Y Avg
2.17x
5Y Avg
3.33x
Market Cap
$987.72M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$994.10M
EV/Sales Ratio
2.50x
TTM Avg
4.19x
3Y Avg
12.20x
5Y Avg
19.04x
Market Cap
$959.28M
EV/Sales Ratio
88.27x
TTM Avg
120.79x
3Y Avg
120.79x
5Y Avg
120.79x
Market Cap
$1.01B
EV/Sales Ratio
N/A
TTM Avg
38.08x
3Y Avg
38.08x
5Y Avg
38.08x
Market Cap
$957.83M
EV/Sales Ratio
N/A
TTM Avg
60100.68x
3Y Avg
43581.59x
5Y Avg
27036.85x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $984.47M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $986.75M | 2.40x | 16.24x | 25.95x | 23.23x |
| Pacira BioSciences, Inc. (PCRX)vs › | $971.96M | 1.58x | 1.77x | 2.17x | 3.33x |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $987.72M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $994.10M | 2.50x | 4.19x | 12.20x | 19.04x |
| Vor Biopharma Inc. (VOR)vs › | $998.37M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $959.28M | 88.27x | 120.79x | 120.79x | 120.79x |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | N/A | 38.08x | 38.08x | 38.08x |
| Savara Inc. (SVRA)vs › | $957.83M | N/A | 60100.68x | 43581.59x | 27036.85x |
| Immatics N.V. (IMTX)vs › | $1.01B | 15.64x | 15.40x | 10.40x | 9.15x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
